Aurobindo’s European subsidiary is set to acquire Actavis’s commercial generic operations in seven Western European markets in a deal worth about €30 million ($40 million).
South African drug companies have been accused by advocacy organisations of planning a "deceptive" campaign to delay new laws which could see the introduction of more generic medicines.
A US judge has said Teva Pharmaceuticals did not infringe patents belonging to a rival company after seeking approval to market a generic version of the drug.
EIP has hired IP litigator Matthew Jones from Teva Pharmaceuticals Europe as a partner.
Viagra-maker Pfizer Ltd and Teva Pharmaceutical Industries have agreed to settle patent litigation related to Teva’s generic version of Viagra (sildenafil citrate) tablets.
The US Food and Drug Administration (FDA) has approved the first generic versions of antidepressant drug Cymbalta (duloxetine hydrochloride), after Eli Lilly’s primary patent covering the product expired on December 11.
The High Court in Australia has said for the first time that a method of medical treatment for the human body can be a patentable invention.
Six US congressman have implored President Barack Obama to ensure that the Trans Pacific Partnership does not include measures that undermine access to affordable healthcare.
At the 3rd C5 Forum on Biosimilars in London on Wednesday, a panel of lawyers and regulatory experts discussed the lie of the land for biosimilars.
Novartis Pharmaceuticals has filed a lawsuit against US drug manufacturer Roxane Laboratories disputing an application for a schizophrenia drug.